Traders Buy High Volume of Ventyx Biosciences Call Options (NASDAQ:VTYX)

Ventyx Biosciences, Inc. (NASDAQ:VTYX) was the target of unusually large options trading on Tuesday. Traders purchased 2,207 call options on the stock. This represents an increase of approximately 299% compared to the typical daily volume of 553 call options.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating on shares of Ventyx Biosciences in a research report on Tuesday, January 14th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC grew its stake in shares of Ventyx Biosciences by 273.1% in the third quarter. Barclays PLC now owns 80,295 shares of the company’s stock valued at $175,000 after buying an additional 58,776 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Ventyx Biosciences by 44.4% during the fourth quarter. Rhumbline Advisers now owns 132,825 shares of the company’s stock valued at $291,000 after purchasing an additional 40,813 shares during the period. State Street Corp lifted its position in shares of Ventyx Biosciences by 0.8% during the third quarter. State Street Corp now owns 1,187,650 shares of the company’s stock worth $2,589,000 after purchasing an additional 9,783 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Ventyx Biosciences by 2.0% in the third quarter. JPMorgan Chase & Co. now owns 1,007,519 shares of the company’s stock valued at $2,196,000 after purchasing an additional 20,236 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Ventyx Biosciences by 5.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,391,702 shares of the company’s stock valued at $3,034,000 after purchasing an additional 77,350 shares in the last quarter. 97.88% of the stock is owned by institutional investors and hedge funds.

Ventyx Biosciences Stock Performance

Shares of VTYX traded down $0.07 during trading hours on Tuesday, hitting $1.09. The stock had a trading volume of 846,321 shares, compared to its average volume of 1,243,505. Ventyx Biosciences has a 12-month low of $1.07 and a 12-month high of $5.66. The firm has a market cap of $77.18 million, a P/E ratio of -0.46 and a beta of 0.58. The company’s fifty day simple moving average is $1.62 and its 200 day simple moving average is $2.04.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.13. As a group, sell-side analysts predict that Ventyx Biosciences will post -2.09 earnings per share for the current fiscal year.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.